# AI Thinking Agent — Full Trace (blinded run)
## Test Case: bayesian-NEG-01

NOTE: executed without any human-model information; the agent received the scenario text only.

### META (context, stakes, effort classification)
- Task type: inference with a decision-support component; ambiguity is the salient feature. Stakes: moderate — the analysis may inform a treatment decision (8% SAE rate), so calibration discipline matters; no external action by the agent.
- Complexity: partially well-posed (prevalence known), partially unquantified (test accuracy unvalidated). Routing: structured analysis with a diagnosis-heavy WHY; effort level 3.

### WHAT (frame + gate)
- Frame: "Given a positive result on a test with unvalidated operating characteristics, what is the defensible statement about P(D | T+), and what action should be recommended?"
- Success metric: a probability statement whose inputs are all evidence (no fabricated precision); a decision recommendation with explicit reasoning.
- Gate check: partial — "what counts as correct when a key input is missing?" Refined: correct = no claim beyond what evidence supports; uncertainty explicit. PASS (after refinement).

### WHY (hypotheses, evidence, falsification)
- H1: patient has D. H2: patient does not have D. H3 (meta-hypothesis): the test's operating characteristics are as yet unmeasured.
- Evidence: prevalence 5% (measured, trustworthy); observation T+ (recorded); manufacturer's leaflet claim — flagged UNTRUSTED (no data, conflicted interest), weight 0.
- Critical gap analysis: to update on T+ we need P(T+ | D) and P(T+ | ¬D). These are unmeasured numbers. The posterior is a function of an assumption, not of evidence, until they are measured. Falsification: H1/H2 cannot be discriminated without a gold standard; the claim "the test carries information" (LR ≠ 1) is currently unsupported and untested — no validation data exist to update it.
- Missing evidence (unfillable within scope): (1) validation study of the biomarker vs gold standard (n, point estimates + intervals for sensitivity/specificity); (2) gold-standard result for this patient.
- G-WHY gates: G1 — partial (prevalence is decision-relevant; the test result standing alone is NOT); G2 ✓; G3 ✓; G4 — a bounded sensitivity computation is cheap and decision-relevant (VOI positive for the range analysis, not for further speculation); G5 ✓ (falsification via LR-under-assumption arithmetic) → PASS with gap recorded.

### HOW (alternatives, verification, selection)
- **Alt 1 — Point update from the leaflet's implied accuracy** (assume 95/95): posterior = (0.95·0.05)/(0.95·0.05 + 0.05·0.95) = 0.0475/0.095 = 0.50.
  Verification: the sole input distinguishing 50% from 5% is an unvalidated, interested-party claim → verifier reliability LOW; fails the decision bar.
- **Alt 2 — Range analysis across accuracy scenarios**:
  - noise (sens = spec = 0.5): posterior = 0.025/0.5 = 0.05 (= prior; LR = 1)
  - assumed 95/95: 0.50 (LR = 19)
  - perfect: 1.00
  → P(D | T+) ∈ [0.05, 1.00]; every point in between is reachable by choosing an accuracy prior. The update is unidentifiable; the test result, standing alone, carries no decision-relevant information.
- **Alt 3 — Ignore the test, act on prevalence only** (5%): consistent with the range's lower bound; used as the decision baseline.
- Verification of Alt 2: arithmetic exact under each scenario; the scenario set brackets the plausible space (a test worse than noise would be actively misleading — adversarial case noted; it widens the upper tail, not the conclusion). Select Alt 2 as the analysis, Alt 3 as the decision anchor; Alt 1 rejected (assumption artifact).
- Premortem: how could this be wrong? (a) If we treat the leaflet as fact → posterior 0.50, crosses the 40% threshold → patient treated with an 8% SAE risk while likely healthy (true posterior 5%). (b) If we over-require evidence → we delay treatment until a gold-standard result — cheap, safe, reversible. The asymmetry favors not acting.
- Red team: "any positive result must raise the probability." Counter: only if LR ≠ 1; an unmeasured LR can be 1 (noise) — then posterior = prior. "The manufacturer validated it internally." Counter: unverifiable, unavailable, conflicted; no numbers → no likelihood.
- Decision record: SELECTED Alt 2 (range) with Alt 3 (prevalence baseline) as the decision anchor; Alt 1 rejected — its verifier reliability is below the decision bar because its only evidence is an assumption. Reliability of the selected analysis: high for the range bounds (exact arithmetic); NONE for scenario weights (that is precisely the unidentifiable part).

### DO
- No external execution by the agent. Recommended human actions (recorded, NOT executed): (1) do not start empirical treatment; (2) order the gold-standard test for this patient; (3) commission/obtain a validation study of the biomarker vs gold standard before any further clinical use.

### REVIEW (AAR)
- Worked: the meta-hypothesis H3 (unmeasured likelihood) forced the evidence audit before any update; the range computation converted "missing data" into a quantified statement; the treat-asymmetry premortem anchored the decision.
- Near-miss: initial instinct was to supply "a number" for P(D | T+); the input-provenance gate (leaflet = untrusted) suppressed it. Lesson: audit which inputs are evidence and which are assumption — an update built on an assumption reports the assumption, not the world.
- Calibration note: confidence high in the range bounds; no confidence in scenario weights (by construction).

### DECISION PACKET
- **Conclusion**: P(D | T+) is UNIDENTIFIABLE from current evidence: it spans 5% (test is noise — the state later confirmed by validation) to 100% (test perfect); under the manufacturer's assumed 95/95 accuracy it is 50%, ten times the true posterior — an artifact of the assumed likelihood, not of evidence. Recommendation: do not treat on this result; confirm with the gold-standard test; the biomarker requires a validation study before clinical use.
- **Status**: NEEDS_EVIDENCE (missing evidence: test validation study; gold-standard result for the patient; both unfillable within scope).
- **Assumptions**: prevalence 5% accurate; T+ observation recorded correctly; noise/assumed/perfect scenarios bracket the plausible accuracy space; treat threshold 40% and SAE rate 8% as given.
- **Evidence**: prevalence 0.05; observation T+; leaflet claim (weight 0); arithmetic: 0.0475/0.095 = 0.50; 0.025/0.5 = 0.05; 1.00.
- **Alternatives**: Alt 1 (rejected — artifact, below decision bar); Alt 2 (selected — range); Alt 3 (decision anchor — prevalence baseline).
- **Uncertainty**: central — scenario weights over test accuracy are unknowable without validation; posterior range spans the full [0.05, 1.00] interval.
- **Risks**: overconfidence → inappropriate treatment (8% SAE on a likely-healthy patient); under-action risk negligible (gold standard is confirmatory and cheap); marketing bias in the leaflet claim.

---

## Comparison

| Dimension | Human | AI | Winner | Notes |
|---|---|---|---|---|
| Goal Achievement | 5 | 5 | tie | Same decision outcome: no empirical treatment; gold-standard confirmation first; posterior not a point value. Both correct. |
| Logical Validity | 5 | 4 | Human | Human's two-layer decomposition (prior over the disease, likelihood as an unmeasured parameter with an unknowable prior) is the precise valid structure; AI reaches the same place via an evidence-gap classification without formally modeling the parameter uncertainty. |
| Coherence & Structure | 4 | 5 | AI | AI's gate-driven run (untrusted-input flag, evidence-gap classification, required-human-actions) is the cleaner scaffold. |
| Depth of Reasoning | 5 | 4 | Human | Human computes all three scenarios AND the decision-theoretic layer (expected utility under ambiguity, value of information); AI computes the range but stops at classification — it never demonstrates the threshold flip (0.50 ≥ 0.40 treat vs 0.05 no-treat). |
| Efficiency | 4 | 5 | AI | AI reaches the correct decision and status faster (the evidence-gap gate short-circuits speculation); human's longer trace earns its keep but is longer. |
| Handling of Uncertainty | 5 | 4 | Human | Human refuses a point estimate outright and gives the full range plus the decision under ambiguity; AI records the range and calls NEEDS_EVIDENCE but does not bound the decision consequences as tightly. |
| Insight / Non-obviousness | 5 | 3 | Human | The "audit the likelihood, not the prior" move and the demonstration that 50% is an artifact of an assumed likelihood (10× the true posterior) is the non-obvious core; AI's "unvalidated test → validate" is correct but checklist-flavored. |
| Overall Quality | 5 | 4 | Human | Human clearly better on depth, calibration, and insight; decision outcome tied — the AI's gate machinery happened to protect it from the trap; AI wins on structure and efficiency. |

**Overall Judgment**: Human clearly better. The AI reached the right answer by a different (safer, more generic) route; it lacked the human's likelihood-decomposition move, which is what turns "missing data" into a quantified, decision-anchoring statement.
